It affirmed its senior unsecured rating and rating on senior unsecured notes at BB. The outlook is stable. The IDR has been removed from rating watch positive, on which it was placed on November 12, 2019.
The upgrade follows completion of demerger of life science ingredient business of its parent Jubilant Pharmova Ltd (earlier known as Jubilant Life Sciences Ltd) into a separate entity, and transfer of debt and cash.
Fitch said the upgrade reflects improvement in business profile, which will outweigh a slight loss of diversification.
JPL's limited dependence on generic formulations and favourable market position in speciality pharmaceutical-focused segments along with a strong financial profile continue to underpin its credit profile.
Fitch said this is despite the company's small size and high degree of regulatory risk arising from limited production facility diversification.
Singapore, Feb 18
Fitch Ratings on Thursday upgraded Jubilant Pharma Ltd's (JPL's) long-term foreign currency issuer default rating to BB from BB-minus.
Disclaimer: This story was supplied by an external content provider; we do not endorse or accept responsibility for its accuracy, completeness, or any outcomes from relying on it. It is for informational purposes only and does not constitute legal, financial, medical, or other professional advice. Laws and regulations vary and may change; readers should verify accuracy and compliance with local requirements and consult a qualified professional for tailored guidance.
